Brief: Mirum Pharmaceuticals Q3 EPS USD 0.05
04/11/2025 21:01
Nov 04 (Reuters) - Mirum Pharmaceuticals Q3 product sales USD 133.01 million. Q3 operating expenses USD 130.407 million Q3 net income USD 2.905 million Q3 operating income USD 2.603 million
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX